Repare Therapeutics Inc (RPTX) - Total Liabilities
Based on the latest financial reports, Repare Therapeutics Inc (RPTX) has total liabilities worth $11.62 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Repare Therapeutics Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Repare Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Repare Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.
Repare Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Repare Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kirana Megatara Tbk PT
JK:KMTR
|
Indonesia | Rp3.35 Trillion |
|
CONDOR ENERGIES INC.
F:WQ6
|
Germany | €76.61 Million |
|
Afyon Cimento Sanayi TAS
IS:AFYON
|
Turkey | TL1.11 Billion |
|
ELEMENT 29 RESOURCES INC
F:2IK
|
Germany | €1.50 Million |
|
Global Green Chemicals Public Company Limited
BK:GGC
|
Thailand | ฿1.61 Billion |
|
Chinyang Hold
KO:100250
|
Korea | ₩247.70 Billion |
|
LG HelloVision Corp
KO:037560
|
Korea | ₩803.70 Billion |
|
Safari Investments RSA Ltd
JSE:SAR
|
South Africa | ZAC1.57 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Repare Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RPTX stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Repare Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Repare Therapeutics Inc (2018–2024)
The table below shows the annual total liabilities of Repare Therapeutics Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $25.38 Million | -39.32% |
| 2023-12-31 | $41.82 Million | -50.54% |
| 2022-12-31 | $84.56 Million | +5.31% |
| 2021-12-31 | $80.29 Million | +14.29% |
| 2020-12-31 | $70.26 Million | +447.72% |
| 2019-12-31 | $12.83 Million | -64.67% |
| 2018-12-31 | $36.31 Million | -- |
About Repare Therapeutics Inc
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camo… Read more